Updated Announcement—AAPS and FDA Agreement to Build Quantitative Alzheimer’s Disease Model

Journal Title: The AAPS Journal - Year 2008, Vol 10, Issue 2

Abstract

Authors and Affiliations

Peter Inchauteguiz

Keywords

Related Articles

A general procedure for the enantioselective synthesis of the minor tobacco alkaloids nornicotine, anabasine, and anatabine

The minor tobacco alkaloids nornicotine, anabasine, and anatabine fromNicotiana tobacum are known to possess nicotinic receptor agonist activity, although they are relatively less potent than S-(−)-nicotine, the...

Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments

Multiple outputs or measurement types are commonly gathered in biological experiments. Often, these experiments are expensive (such as clinical drug trials) or require careful design to achieve the desired information co...

Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

The online version of the original article can be found at http://dx.doi.org/10.1208/s12248-015-9782-0.

Controlled Crystallization of the Lipophilic Drug Fenofibrate During Freeze-Drying: Elucidation of the Mechanism by In-Line Raman Spectroscopy

We developed a novel process, “controlled crystallization during freeze-drying” to produce drug nanocrystals of poorly water-soluble drugs. This process involves freeze-drying at a relatively high tempera...

Download PDF file
  • EP ID EP681567
  • DOI  10.1208/s12248-008-9051-6
  • Views 75
  • Downloads 0

How To Cite

Peter Inchauteguiz (2008). Updated Announcement—AAPS and FDA Agreement to Build Quantitative Alzheimer’s Disease Model. The AAPS Journal, 10(2), -. https://europub.co.uk/articles/-A-681567